Story
TriSalus Life Sciences Stock Soars on FDA Clearance for New Drug Delivery Device
Summary
Shares of TriSalus Life Sciences (NASDAQ: TLSI) jumped 29% after the U.S. Food and Drug Administration granted 510(k) clearance for its TriNav Advance device, expanding its portfolio for targeted cancer therapies.
Shares of TriSalus Life Sciences (NASDAQ: TLSI) surged 29% after the company announced it received 510(k) clearance from the U.S. Food and Drug Administration for its TriNav Advance device, a new addition to its therapeutic delivery system portfolio.
FDA Greenlights TriNav Advance
The regulatory clearance allows TriSalus to market TriNav Advance, a new component of its Pressure-Enabled Drug Delivery (PEDD) platform. According to the company's announcement, the device is designed to give interventional radiologists more flexibility and precision when delivering therapeutics.
This clearance expands the company's offerings for liver-directed therapy and also supports a broader range of embolization procedures beyond the liver. TriSalus stated it plans to begin a limited market release of the new device in the coming weeks.
Enhanced Capabilities for Targeted Therapy
The TriNav Advance system is engineered to improve therapeutic delivery in complex cases. It expands the PEDD portfolio by enabling access to smaller, more distant blood vessels. Key features highlighted by TriSalus include:
Ad- Microcatheter Compatibility: It allows physicians to pair the device with a compatible microcatheter of their choice, adapting to various procedures and patient anatomies.
- Dual-Mode Functionality: The device can operate in a "telescoping mode" with a microcatheter for selective delivery or a "high-flow mode" that functions like a standard TriNav device.
Strategic Importance and Market Impact
Company executives framed the clearance as a significant step in enhancing treatment options. Mary Szela, President and CEO of TriSalus, said the device enhances the company’s portfolio "in support of the full range of liver embolization procedures."
Richard Marshall, the company's Chief Medical Officer, added that the clearance enables TriSalus to expand its impact, particularly in cases involving "tortuous anatomies." He noted it allows physicians to "optimize therapeutic delivery in difficult cases while limiting exposure to unaffected anatomical structures."
Read next
More on Stocks
Frontier Nuclear Pins Hopes on Royalty Deal and Namibia Resource Data
Micro-cap uranium explorer Frontier Nuclear Minerals is facing two key valuation catalysts: a zero-cost royalty agreement for a U.S. project and an upcoming resource estimate for its Engo Valley asset in Namibia.
Airtel Money Reportedly Nearing London IPO Filing with $8-$9 Billion Valuation Target
Airtel Money, the mobile payments arm of Airtel Africa, is expected to file for a London Stock Exchange listing as early as this week, targeting a valuation of up to $9 billion, according to a Financial Times report.
Fitch Upgrades ONEOK Credit Rating to 'BBB+' After Apollo Investment
Fitch Ratings has raised ONEOK's long-term credit rating to 'BBB+' from 'BBB' with a stable outlook, citing a significant reduction in leverage following a major equity investment from Apollo Global Management.
Sixth Street Renews Bid for Brighthouse Financial Amid Scrutiny of Existing Deal, Bloomberg Reports
Sixth Street has reportedly revived its offer to acquire insurer Brighthouse Financial, as the company's current sale agreement with Aquarian Holdings faces a regulatory review over its funding.